EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Molecular Stratification of Antiphospholipid Syndrome Through Integrative Analysis of the Whole‐Blood RNA Transcriptome

Amala Ambati, Feiyang Ma, Katarina Kmetova iD, Sherwin Navaz, Claire K Hoy, Cyrus Sarosh, Ajay Tambralli, Erika Navarro-Mendoza, Johann E Gudjonsson, J Michelle Kahlenberg iD, Jacqueline A Madison, Alí Duarte-García iD und 2 weitere

Arthritis & Rheumatology · 2026

DOI: 10.1002/art.70021 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Arthritis & Rheumatology, 2026. Verfasst von Amala Ambati und 13 weiteren Autor:innen. Beteiligte Einrichtung: Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor. Hauptthemen laut MEDLINE: Antiphospholipid Syndrome, Transcriptome. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAMS NIH HHS, NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Antiphospholipid syndrome (APS) is a thromboinflammatory disorder characterized by clinical and mechanistic heterogeneity that complicates early diagnosis and hinders targeted treatment. We aimed to identify distinct molecular endotypes among antiphospholipid antibody (aPL)–positive patients using whole‐blood transcriptomics.

Methods

Whole‐blood RNA sequencing was performed on 174 aPL‐positive patients, including those with primary APS (n = 102), secondary APS (n = 29), and aPL positivity without classifiable APS (n = 43). Unsupervised machine learning and immune cell deconvolution defined transcriptomic clusters and immune landscapes.

Results

Four transcriptionally distinct clusters were identified. At one end of the spectrum, cluster 1 showed up‐regulation of ribosomal and metabolic pathways and down‐regulation of mechanistic target of rapamycin (mTOR), NETosis, and Hippo/interleukin‐6 (IL‐6) signaling. In contrast, cluster 4 exhibited the opposite pattern, with strong up‐regulation of mTOR, NETosis, and Hippo/IL‐6 signaling. Cluster 2 demonstrated modest enrichment in messenger RNA processing and amino acid metabolism, and cluster 3 showed biosynthetic suppression with mild Hippo/IL‐6 activation. Clinically, cluster 4 stood out with higher IgG anticardiolipin and anti–β 2 ‐glycoprotein I positivity, elevated neutrophil counts, and increased urine protein‐to‐creatinine ratios. Immune deconvolution revealed distinct cell type profiles: cluster 1 was lymphoid predominant; cluster 2 had a balanced composition; cluster 3 was enriched in Treg cells, natural killer cells, macrophages, mast cells, and memory B cells; and cluster 4 was dominated by myeloid cells, including neutrophils, eosinophils, and dendritic cells. Distinct immune pathway activations were linked to clinical features, including white matter lesions, seizures, and cardiac valve disease.

Conclusion

This study reveals four endotypes of aPL‐positive patients, a step toward personalized medicine for APS through pathway‐informed stratification and therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiphospholipid SyndromeTranscriptomeHumansFemaleMaleAdultMiddle AgedTOR Serine-Threonine KinasesAntibodies, AntiphospholipidInterleukin-6Protein Serine-Threonine KinasesSequence Analysis, RNASignal Transduction

Substanzen

TOR Serine-Threonine KinasesAntibodies, AntiphospholipidInterleukin-6Protein Serine-Threonine KinasesMTOR protein, human

Autor:innen und Institutionen

  • Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor.
  • ProMedica Rheumatology, ProMedica Toledo Hospital, Sylvania, Ohio.
  • Department of Dermatology, University of Michigan, Ann Arbor.
  • Department of Rheumatology, Mayo Clinic, Rochester, Minnesota.
  • Division of Pediatric Rheumatology, Department of Pediatrics, University of Michigan, Ann Arbor.

ORCID-Profile: Katarina Kmetova, J Michelle Kahlenberg, Alí Duarte-García, Jason S Knight, Yu Zuo

Förderung

  • NIAMS NIH HHS
  • NHLBI NIH HHS

Zitieren

APA

Ambati, A., Ma, F., Kmetova, K., Navaz, S., Hoy, C. K., Sarosh, C., Tambralli, A., Navarro-Mendoza, E., Gudjonsson, J. E., Kahlenberg, J. M., Madison, J. A., Duarte-García, A., Knight, J. S., & Zuo, Y. (2026). Molecular Stratification of Antiphospholipid Syndrome Through Integrative Analysis of the Whole‐Blood RNA Transcriptome. Arthritis & Rheumatology. https://doi.org/10.1002/art.70021

Vancouver

Ambati A, Ma F, Kmetova K, Navaz S, Hoy CK, Sarosh C, et al. Molecular Stratification of Antiphospholipid Syndrome Through Integrative Analysis of the Whole‐Blood RNA Transcriptome. Arthritis & Rheumatology. 2026. doi:10.1002/art.70021

BibTeX
@article{Ambati2026,
  author = {Ambati, Amala and Ma, Feiyang and Kmetova, Katarina and Navaz, Sherwin and Hoy, Claire K and Sarosh, Cyrus and Tambralli, Ajay and Navarro-Mendoza, Erika and Gudjonsson, Johann E and Kahlenberg, J Michelle and Madison, Jacqueline A and Duarte-García, Alí and Knight, Jason S and Zuo, Yu},
  title = {Molecular Stratification of Antiphospholipid Syndrome Through Integrative Analysis of the Whole‐Blood RNA Transcriptome},
  journal = {Arthritis & Rheumatology},
  year = {2026},
  doi = {10.1002/art.70021}
}
Kostenlos starten →